Skip to content
PIL Logo

OPDIVO 10 mg/mL concentrate for solution for infusion

Last Updated on eMC 07-Jun-2017 View changes  | Bristol-Myers Squibb Pharmaceutical Limited Contact details

Black Triangle icon This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Please click on the link to the left to view the PIL in PDF format.

Certain risk materials on this website are intended for use by healthcare professionals only.

By proceeding you are confirming that you are a healthcare professional.

Want to avoid this message? If you are a Healthcare professional, REGISTER or LOGIN and you will not have to self-certify when you access Risk Minimisation Materials.

You can leave feedback on specific Risk Minimisation Materials or make general observations about how they are displayed on the eMC by leaving comments in the box below.

Please note that we are unable to respond to medical queries.

OPDIVO 10 mg/mL concentrate for solution for infusion


Please enter your email address below

Tick here if you wish to recieve a response to your feedback

Risk Materials
VIEW

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Opdivo (nivolumab) Important Safety Information To Minimise The Risks Of Immune-Related Adverse Reactions

This risk minimisation material is a condition of the marketing authorisation. This document is essential to ensure the safe and effective use of nivolumab or nivolumab in combination with ipilimumab, and appropriate management of immune-related adverse reactions which may include pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, skin reactions and other immune-related adverse reactions, as well as potential complications of allogeneic Haematopoietic Stem Cell Transplant (HSCT) in classical Hodgkin Lymphoma.

If you would like a hard copy of the Opdivo risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; e-mail: medical.information@bms.com) with your specific request.

For Healthcare Professionals

Opdivo (nivolumab) Patient Alert Card

This risk minimisation material is a condition of the marketing authorisation.

Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab.

CLOSE THIS PANEL

Company contact details

Bristol-Myers Squibb Pharmaceutical Limited

Company image
Address

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, UK

Medical Information Direct Line

+44 (0) 800 731 1736

Telephone

+44 (0)1895 523 000

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

nivolumab

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue